Zobrazeno 1 - 10
of 478
pro vyhledávání: '"35"'
Publikováno v:
Transplantation proceedings. 51(10)
This study reports a single-arm trial in the interim phase in 4 patients with median age of 40.5 years who have undergone combined HLA-matched sibling donor (MSD) stem cell graft and an unrelated cord blood (UCB) unit for the treatment of severe apla
Autor:
Alain Delmer, Nicolas Boissel, Aliénor Xhaard, Jérôme Larghero, Gérard Socié, Marie Sebert, R P de Latour, Chantal Himberlin, Lionel Adès, Emmanuel Raffoux, Marie Robin, Hervé Dombret, Nathalie Dhedin, Pierre Fenaux, Raphaël Porcher
Publikováno v:
Bone Marrow Transplantation. 50:74-81
Allogeneic hematopoietic stem cell transplantation provides the best chance of long-term survival for patients with AML, but is associated with an unpredictable risk of treatment-related mortality. From January 2000 to December 2010, we compared the
Autor:
L Wood, Peter Jacobs
Publikováno v:
Bone marrow transplantation. 42
Bone marrow was the traditional graft source when we introduced these procedures to South Africa. Technical details were established using rabbits as the experimental model with translation into a formally structured clinical programme at the Univers
Autor:
Raphaël Porcher, Régis Peffault de Latour, Lionel Ades, Emmanuel Raffoux, Alain Delmer, Gérard Socié, Jérôme Larghero, Chantal Himberlin, Hervé Dombret, Marie Robin, Marie Sebert, Pierre Fenaux, Nathalie Dhedin, Aliénor Xhaard
Publikováno v:
Blood. 120:3103-3103
Abstract 3103 Introduction: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) provides the best chance of long-term survival for patients with intermediate or high-risk acute myeloid leukemia (AML). The major limitation of this procedure is t
Autor:
H. Jardel, S. Le Tortorec, Anne-Sophie Moreau, Claude-Eric Bulabois, Noel-Jean Milpied, J-L Harousseau, Marc-André Mahé, H Maisoneuve, Béatrice Mahé, M. J. Rapp, Philippe Moreau, Mohamed Hamidou, Benoit Dupas, Sylvain Bourdin, Nadine Morineau
Publikováno v:
Leukemialymphoma. 30(3-4)
Thirty-five adult patients with high-risk HD (HD) defined by (1) Ann Arbor stage IV or bulky nodal disease (tumor/thorax ratio > 0.45) and (2) no or partial response (PR) (< 75%) to the initial 3 courses of ABVD, received an early intensive therapy w
Autor:
Atsuko Tsukamoto, Fumio Kawano, Shoichi Nagakura, Yoshiko Inoue, Toshiro Kawakita, Takahiro Matsui, Michihiro Hidaka, Tetsuyuki Kiyokawa, Tatsunori Sakai, Shigeki Takemoto
Publikováno v:
Blood. 110:5037-5037
Adult T cell leukemia/lymphoma (ATL) has a high incident in Japanese. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) against ATL made the patients’ survival longer than chemotherapy alone. Actually, some of them became long survivor
Autor:
Nicholas J. Short, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Xuelin Huang, Hagop M. Kantarjian, Tapan M. Kadia, Partow Kebriaei, Zeev Estrov, Jorge E. Cortes, David Marin, Koichi Takahashi, Marina Konopleva, Yogin B Patel, Deborah A. Thomas, Susan O'Brien, Nitin Jain, Koji Sasaki, Guillermo Garcia-Manero, Michael Rytting, Richard E. Champlin, Maria Khouri
Publikováno v:
JAMA oncology. 4(2)
Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective To evaluate the
Autor:
Hilary Haines, Lindsey Hornung, Rebecca A. Marsh, Stella M. Davies, Jack J. Bleesing, Michael B. Jordan, Alexandra H. Filipovich
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:288-292
Mixed donor chimerism is increasingly common in the pediatric hematopoietic stem cell transplantation (HSCT) setting because of the increased use of reduced-intensity preparative regimens for nonmalignant diseases. Donor lymphocyte infusion (DLI) is
Autor:
Olivier Hermine, Denis Caillot, Karine Celli-Lebras, Céline Berthon, Arnaud Pigneux, Emmanuel Raffoux, Sylvie Chevret, Jean-Pierre Marolleau, Oumedaly Reman, Emilie Lemasle, Hervé Dombret, Norbert Vey, Stéphane de Botton, Xavier Thomas, Jean-Yves Cahn, Marc A. Simon, Claude Preudhomme, Norbert Ifrah, Christian Recher, Sylvie Castaigne, Christine Terré
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩
Journal of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (11), pp.1223-1230. ⟨10.1200/JCO.2016.70.4551⟩
Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leukemia (AML). Patients and Methods Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56560a3634aa7e800e79c4d507e88223
https://u-bourgogne.hal.science/hal-01557436
https://u-bourgogne.hal.science/hal-01557436
Autor:
Fevzi Firat Yalniz, Mark R. Litzow, William J. Hogan, Mrinal M. Patnaik, Robert C. Wolf, Moussab Damlaj, Hassan B. Alkhateeb, Kristen B. McCullough, Mehrdad Hefazi, Ankit Kansagra
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 23(9)
Acute graft-versus-host disease (aGVHD) is the leading cause of morbidity and mortality after allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first-line treatment; however, less than one-half of patients achieve durable re